| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 15.138 | 19.187 | 18.592 | 17.167 | 12.847 | 18.063 | 18.688 | 23.530 | 25.707 | 23.517 |
| Total Income - EUR | 15.138 | 19.187 | 18.592 | 17.167 | 12.847 | 18.063 | 18.688 | 23.530 | 25.707 | 23.517 |
| Total Expenses - EUR | 2.189 | 2.412 | 5.485 | 6.726 | 6.548 | 6.250 | 6.897 | 11.127 | 10.483 | 11.501 |
| Gross Profit/Loss - EUR | 12.949 | 16.775 | 13.107 | 10.441 | 6.298 | 11.813 | 11.791 | 12.403 | 15.225 | 12.015 |
| Net Profit/Loss - EUR | 12.495 | 16.200 | 12.921 | 10.269 | 6.179 | 11.633 | 11.604 | 12.168 | 14.469 | 11.346 |
| Employees | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Check the financial reports for the company - Citocervix Lab Srl
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 53 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Assets | 310 | 6.511 | 9.577 | 10.320 | 6.228 | 11.750 | 11.653 | 12.226 | 17.114 | 12.509 |
| Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 281 | 1.174 | 1.145 | 1.919 | 2.391 | 297 | 1.185 | 4.292 | 10.594 | 9.265 |
| Cash | 29 | 5.336 | 8.432 | 8.401 | 3.837 | 11.453 | 10.467 | 7.934 | 6.520 | 3.244 |
| Shareholders Funds | 53 | 6.511 | 9.577 | 10.320 | 6.228 | 11.681 | 11.653 | 12.216 | 14.517 | 11.394 |
| Social Capital | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 | 40 |
| Debts | 309 | 0 | 0 | 0 | 0 | 69 | 0 | 10 | 2.597 | 1.115 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 5.0415 | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 |
| Main CAEN | "8691 - 8691" | |||||||||
| CAEN Financial Year |
8690
|
|||||||||
Comments - Citocervix Lab Srl